Rectal Cancer Therapeutics Pipeline is Witnessing Significant Growth due to Growing Need for Targeted Therapies: P&S Market Research

NEW YORK, March 29, 2018 -- According to a new research report titled “Rectal Cancer Therapeutics Pipeline Analysis 2018” published by P&S Market Research, Rectal cancer therapeutics currently exhibits a proliferating pipeline with 15 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/rectal-cancer-therapeutics-pipeline-analysis/report-sample

Rectal cancer is a disease in which malignant (cancer) cells are formed in the tissues of the rectum. The rectum is the lower part of the colon that connects the large bowel to the anus. It starts at the end of the final segment of the colon and ends when it reaches the short, narrow passage leading to the anus. Adenocarcinomas or cancer in the epithelium, comprise the vast majority of colon and rectal cancers; some of the rare rectal cancers include lymphoma, carcinoid and sarcoma. It has been observed that, there are no early symptoms of rectal cancer, but some of the generalized symptoms include, pain in rectum, change in appetite, fatigue or tiredness, unintended weight loss and stomach cramps.

According to the research findings, most of the drug candidates for the treatment of rectal cancer are being developed to be administered by the intravenous and the oral route. The main advantage associated with the intravenous route is that the drug can easily be entered the bloodstream, or lymph vessels. Also, medication can be easy to take through the oral route, additionally the route has very less patient non-compliance.

Browse Full Report with detailed TOC on “Rectal Cancer Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/rectal-cancer-therapeutics-pipeline-analysis

It has been observed that, rise in geriatric population and increasing incidence of rectal cancer has been driving the growth of the rectal cancer pipeline. Colorectal cancer includes both colon and rectal cancers. According to the National Cancer Institute, in 2017, the incident cases of colorectal cancer were found as 40.1 per 100,000 people per year. The increasing geriatric population is mostly frail and unable to tolerate the treatments such as radiation therapy and chemotherapy for the treatment of cancer. This is one of the most prominent factor due to which companies are focusing towards development of therapeutics for the treatment of rectal cancer.

Some of the key players involved in the development of rectal cancer therapeutics include Taiwan Liposome Company, Sanofi and Advaxis Inc.

More Reports Published by P&S Market Research

PI3K Inhibitors Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis

Ulcerative Colitis Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook